The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
Hui Yang, Kunlun Wang, Tao Wang, Mengxi Li, Bingxu Li, Shenglei Li, Ling Yuan
Abstract
Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.
Topics & Concepts
MedicineEsophageal cancerPD-L1ImmunotherapyOncologyClinical trialCancerInternal medicineCombination therapyCancer Immunotherapy and BiomarkersEsophageal Cancer Research and TreatmentPancreatic and Hepatic Oncology Research